Authors

  • M. Hamidova
    Bukhara State Medical Instituti named after Abu Ali ibn Sino

DOI:

https://doi.org/10.71337/inlibrary.uz.ijms.71664

Abstract

Bacterial vaginosis (BV) is one of the most common infectious pathologies of women of childbearing age. Bacterial vaginosis is a condition in which the normal vaginal microflora, represented mainly by lactobacilli, is replaced by numerous anaerobic and other opportunistic flora. Dysbiosis has been linked to complications such as rupture of the membranes, premature birth, infections of the chorion, amnion, and amniotic fluid., intrauterine fetal death. This suggests the need for screening for bacterial vaginosis and its treatment before pregnancy.


background image

w

w

w

.a

ca

de

m

icp

ub

lis

he

rs

.o

rg

Vo

lu

m

e

5,

Fe

br

ua

ry

,2

02

5

,

M

ED

IC

AL

SC

IE

N

CE

S.

IM

PA

CT

FA

CT

OR

:7

,8

9

BACTERIAL VAGINOSIS

Hamidova M.G.

hamidova.mushtaribegim@bsmi.uz

+998906135513

Assistant of the Department of Normal Physiology of Bukhara State Medical Instituti named

after Abu Ali ibn Sino

ANNOTATION:

Bacterial vaginosis (BV) is one of the most common infectious

pathologies of women of childbearing age. Bacterial vaginosis is a condition in which the

normal vaginal microflora, represented mainly by lactobacilli, is replaced by numerous

anaerobic and other opportunistic flora. Dysbiosis has been linked to complications such as

rupture of the membranes, premature birth, infections of the chorion, amnion, and amniotic

fluid., intrauterine fetal death. This suggests the need for screening for bacterial vaginosis

and its treatment before pregnancy.

Key words:

Bacterial vaginosis; vaginal microbiocenosis; immune defense mechanisms;

cytokines.

Bacterial vaginosis (BV) is a polymicrobial disease in which the normal vaginal microbiota

(protective lactobacilli) is replaced by microaerophilic (Gardnerella vaginalis) and obligate

anaerobic (

Bacteroides spp., Prevotella spp., Mobiluncus spp., Veillonella spp.,

Medasphaega spp., Leptotrichia spp., Atopobium vaginae

and others) by microorganisms

[1]. There is a generally accepted opinion that there is no inflammatory leukocyte reaction in

BV.

According to world statistics, BV occupies one of the first places among diseases of the

vagina. Its prevalence in the population ranges from 12% to 80% and depends on the

number of women surveyed [1]. BV is detected in 80-87% of women with abnormal vaginal

discharge, in 37-40% of pregnant women, and in 25% of adolescent girls. However, it is not

possible to determine the true incidence of BV due to the fact that approximately 50% of

women have an asymptomatic condition. At the same time, BV is found in 15-19% of

patients in outpatient gynecological practice, in 10-40% of pregnant women, in 24-40% of

women with STIs, and in 35% of women with PID (pelvic inflammatory disease).

BV is not an STI and does not pose a danger to life, however, it becomes a risk factor for

pregnancy complications, as well as a cause of the development of PID [2].

Important components of the vaginal indigenous (resident, obligate, predominant in the

biotope) microflora are lactobacilli, bifidobacteria and propionic acid bacteria, which must

be at least 95% in this biotope in order for the protection of the vagina to be effective. The

evolution of the vaginal biotope has led to the development of adaptive mechanisms that

allow these indigenous microorganisms to actively develop in the vaginal environment,

adhere to the epithelium, forming strong symbiotic bonds with it, and successfully compete

with facultative and transient opportunistic and pathogenic microflora.


background image

w

w

w

.a

ca

de

m

icp

ub

lis

he

rs

.o

rg

Vo

lu

m

e

5,

Fe

br

ua

ry

,2

02

5

,

M

ED

IC

AL

SC

IE

N

CE

S.

IM

PA

CT

FA

CT

OR

:7

,8

9

The first place among the indigenous flora is occupied by lactobacilli.

Lactobacillus

сrisраtus

,

L. inеrs

,

L. jеnsеnii

and

L. gаssеri

are most often isolated. The dominant species

is

L. сrisраtus

— they are found in 72% of women with normocenosis.

Lactobacilli are capable of:

• actively reproduce in the vaginal environment;

• adhere to the surface of epitheliocytes, leaving no room for infectious agents;

• Ferment glycogen with accumulation of organic acids;

• synthesize hydrogen peroxide, which is practically the only bactericidal factor that can be

produced in the human div;

• produce lysozyme, bacteriocins;

• Stimulate local immunity.

Lactobacilli are the most adapted to colonize the vagina and protect it from colonization by

opportunistic and pathogenic microorganisms [3].

Bifidobacteria are the second main component of the native flora. Five species are most

common:

Bifidobacterium bifidum

,

B. lоngum

,

B. infаntis

,

B. brеvе

and

B. аdоlеsсеntis

.

They are able to ferment glycogen to form organic acids, thus creating an optimal pH

environment for themselves; adhere to the surface of the epithelium, synthesize

antimicrobial metabolites, and stimulate local immunity. Effectively inhibit the growth of

Gardnerella, Staphylococcus, Escherichia, Klebsiella and other opportunistic

microorganisms. In healthy non-pregnant women, bifidobacteria are contained in lower

concentrations than lactobacilli (up to 107 CFU/ml). During pregnancy (especially in the

prenatal period), their titer increases sharply, which is a powerful factor in protecting the

newborn's div from colonization by pathogenic microorganisms during passage through

the birth canal [4].

The third type of indigenous flora is propionic acid bacteria. These are gram-positive

asporogenic polymorphic small rods that compete well for nutrients with anaerobes. They

are characterized by strict anaerobism, actively ferment glycogen to form propionic and

acetic acids, and inhibit the growth of opportunistic bacteria. They have antioxidant,

antimutagenic, anticarcinogenic and immunostimulating properties.

In general, the normocenosis in the vagina is characterized by a dynamic relationship

between

Lасtоbасillus асidорhilus

(produces hydrogen peroxide, which has a toxic effect on

pathogenic microorganisms and maintains the pH of the vagina) and other endogenous flora.

It depends on the levels of estrogens in the blood plasma; the amount of glycogen in the

epithelium, because acidic environment is produced from it; pH; products of metabolism of

endogenous flora and pathogenic microorganisms.


background image

w

w

w

.a

ca

de

m

icp

ub

lis

he

rs

.o

rg

Vo

lu

m

e

5,

Fe

br

ua

ry

,2

02

5

,

M

ED

IC

AL

SC

IE

N

CE

S.

IM

PA

CT

FA

CT

OR

:7

,8

9

Summing up, we can say that two main factors of protection are decisive — an acidic

environment (pH of the vagina in the range from 3.8 to 4.5) and colonization resistance.

Colonization resistance is understood as a set of mechanisms that ensure the ability of a

microbiota and a macroorganism to cooperatively protect an ecosystem from pathogenic

microflora. Microorganisms within communities come into contact with each other in

different planes and have a minimal free surface for contact with the matrix. Many

microcolonies and similar isolated communities are combined into a common structure — a

biofilm [5].

The colonization properties of native flora depend on its adhesive properties. By attaching to

the surface of epitheliocytes, a biofilm is formed on the vaginal mucosa, consisting of

vaginal mucus, colonies of indigenous microflora and its metabolites. This is one of the

most powerful protective factors, as it prevents adhesion and excessive development of

opportunistic microorganisms.

The causes of disruption of normal microflora can be endogenous and exogenous factors.

Endogenous factors include various hormonal changes during puberty, pregnancy, childbirth,

and abortion; neuroendocrine diseases, hypothyroidism, and diabetes; and disorders in the

local immune system.

Exogenous factors: use of tampons, spermicides; frequent excessive vaginal showering and

douching; change of sexual partner; use of broad-spectrum vaginal pills; therapy with

antibiotics, cytostatic, glucocorticoid, antiviral drugs.

There are five main nosological forms of pathological vaginal discharge: BV, aerobic

vaginitis (AV), vulvovaginal candidiasis (VVC), trichomoniasis vaginitis (TV) and mixed

vaginitis [6].

Exogenous factors: use of tampons, spermicides; frequent excessive vaginal showering and

douching; change of sexual partner; use of broad-spectrum vaginal pills; therapy with

antibiotics, cytostatic, glucocorticoid, antiviral drugs.

There are five main nosological forms of pathological vaginal discharge: BV, aerobic

vaginitis (AV), vulvovaginal candidiasis (VVC), trichomoniasis vaginitis (TV) and mixed

vaginitis [6].

BV is understood as the dysbiotic state of the vaginal flora caused by a sharp increase in the

number of opportunistic pathogens and a sharp decrease in the concentration of lactobacilli,

mainly producing hydrogen peroxide. It affects all areas of a woman's activity and reduces

her quality of life.

The most common complications of BV [7]:

• development of chorionamnionitis;

• premature birth, premature discharge of amniotic fluid (increases by 2.6–3.8 times);


background image

w

w

w

.a

ca

de

m

icp

ub

lis

he

rs

.o

rg

Vo

lu

m

e

5,

Fe

br

ua

ry

,2

02

5

,

M

ED

IC

AL

SC

IE

N

CE

S.

IM

PA

CT

FA

CT

OR

:7

,8

9

• endometritis;

• postpartum sepsis;

• recultivitis after hysterectomy;

• persistence of a latent viral infection;

• creating conditions for colonization of genitourinary organs by STI pathogens;

• tubal infertility (32%), PID (35%).

BV may become a cofactor for the development of papillomavirus infection.

Further studies have shown that, taking into account the similar cytokine gene expression

profile in BV and vaginitis, the traditional view of BV as a non-inflammatory disease is not

entirely correct. Vaginitis and BV are accompanied by a significant increase in the level of

mRNA expression of the IL-6, IL-8, IL-10 genes and a decrease in the content of IL-12a and

IL-18 compared with the control group. Vaginitis also significantly increases the level of

mRNA expression of the IL-1b, TNF, IFN-γ, and CD45 genes.

BV significantly reduces the number of lactobacilli producing hydrogen peroxide, and

polymicrobial, mainly anaerobic, microflora prevails. The primary causative agents of BV

are anaerobic bacteria:

G. vаginаlis

,

Mobiluncus

sрр.,

Bасtеrоidеs

sрр.,

Аtороbium vаginае

.

Currently, progressive researchers identify 2 groups of BV markers [8-10]. Low-specific

ones (defined in both healthy women and BV patients) include

G. vаginаlis

,

Mоbilunсus

sрр.,

Megasphаera

spp.,

Leptotrichia

spp., to the highly specific (detectable only in women

with BV) —

A. vaginae

, vaginosis-associated bacteria

Clostridium phylum

,

Muсinаsе

,

Siаlidаsе

.

Pathogenesis.

The number of lactobacilli producing hydrogen peroxide decreases in the

vagina, while the pH of the vagina increases (pH ≥ 4.5), the growth of anaerobic bacteria

and the release of amines (the smell of rotting fish).

The so—called "key cells" (glue cells) are formed - epithelial cells of the vagina, densely

covered with gram-variable rods (in 70-80% of women with BV).

The clinical picture.

In 50% of patients, the disease is asymptomatic in the presence of

laboratory signs. Patients with BV complain of copious white or gray discharge, often with

an unpleasant odor (rotting fish), especially after unprotected sexual intercourse or during

menstruation. Seminal fluid has a pH of 7.0, so after ejaculation, the pH of the vagina

increases, the amines become free, and being volatile, they cause this odor. Its

intensification in connection with sexual intercourse is a pathognomonic ghost of BV.

As the process progresses, the discharge foams, becomes yellowish-green, thick, slightly

stringy, sticky; 25-30% of women feel burning and itching. Dyspareunia and dysuria occur

[13]. The duration of these symptoms can last for years.


background image

w

w

w

.a

ca

de

m

icp

ub

lis

he

rs

.o

rg

Vo

lu

m

e

5,

Fe

br

ua

ry

,2

02

5

,

M

ED

IC

AL

SC

IE

N

CE

S.

IM

PA

CT

FA

CT

OR

:7

,8

9

Diagnostics.

BV is diagnosed on the basis of the "golden diagnostic standard" — the clinical

and laboratory criteria proposed by R. Amsel [5]:

• homogeneous vaginal discharge;

• pH of vaginal discharge > 4.5;

• positive aminotest result;

• the presence of "key cells" in Gram-stained vaginal discharge smears or in a native

preparation.

The diagnosis is considered confirmed if there are any 3 criteria out of the 4 suggested.

In addition to screening tests, microscopy of a Gram-stained vaginal smear is used to

diagnose BV. The sensitivity and specificity of the method are close to 100%. In addition to

the "key cells", additional signs of BV include the predominance of epithelial cells over

leukocytes and the detection of less than 5 lactobacilli in the visual field when magnified

with immersion.

Treatment.

The requirements for the drug of choice for the treatment of BV are etiotropicity,

a minimum percentage of relapses, convenience of forms and patient compliance, safety,

optimal pharmacoeconomic indicators. The drug of choice should not inhibit the growth of

lactoflora, but contribute to the normalization of microbiocenosis. It is necessary to note

such advantages of local therapy as the absence of systemic action, minimal risk of adverse

reactions, simplicity and convenience of use, absence of contraindications (except for

individual intolerance to the drug), the possibility of use in women with extragenital

pathology (especially in localized forms of the infectious process: acute vulvitis, vaginitis,

cervicitis or exacerbations of chronic processes of the vagina and cervix), rapid entry into

the focus of infection and rapid exposure.

Approaches to the treatment of BV have recently synchronized in the USA (MMVR — STD

treatment Guidelines), Europe (European STD Guidelines) and Russia.

• Clindamycin cream 2% — 5 g in an applicator (single dose) intravaginally once a day (at

night) for 7 days;

• metronidazole gel 0.75% — 5 g (single dose) intravaginally once a day (overnight) for 5

days;

• Metronidazole 500 mg orally 2 times a day for 7 days.

1 g of Metrogil vaginal gel contains 10 mg of the active ingredient metronidazole. It is an

antimicrobial and antiprotozoal agent, a derivative of 5-nitromidazole. The drug is active

against

Triсhоmоnаs vаginаlis

,

Entamoeba histolytica

,

G. vаginаlis

,

Giаrdiа intеstinаlis

,

Lаmbliа

sрр., obligate anaerobes

Bасtеrоidеs

sрр.,

Fusоbасtеrium

sрр.,

Vеillоnеllа

sрр.,

Рrеvоtеllа

. Indications for use are BV and urogenital trichomoniasis.


background image

w

w

w

.a

ca

de

m

icp

ub

lis

he

rs

.o

rg

Vo

lu

m

e

5,

Fe

br

ua

ry

,2

02

5

,

M

ED

IC

AL

SC

IE

N

CE

S.

IM

PA

CT

FA

CT

OR

:7

,8

9

Alcohol and alcohol-containing products should be avoided both during metronidazole

therapy and for 24 hours after its end. If oral metronidazole is intolerant, its intravaginal

administration is also contraindicated.

Metronidazole intravaginal in therapeutic concentration does not inhibit the growth of

vaginal lactobacillus colonies and has a high penetrating ability into the vaginal fluid. The

relative bioavailability of the vaginal gel is 2 times higher than the bioavailability of a single

dose (500 mg) of metronidazole vaginal tablets. It quickly (within 5 days) eliminates clinical

manifestations and provides clinical efficacy reaching 90%. Due to the low concentration in

the blood serum, the risk of side effects is reduced. Finally, and most importantly, the acidic

environment of the Metrogil vaginal gel contributes to the rapid normalization of the vaginal

ecosystem.

When bacteria switch to the growth mode in the biofilm, significant changes occur in the

expression of dozens of bacterial genes in accordance with the stage of colony development

[28]. Potent antibiotics do not affect

G. vаginаlis

films, which contribute to the survival of

most of the pathogenic microflora after the end of antibiotic treatment [27, 29], which leads

to the development of chronic and recurrent forms of the disease.

The first biofilm bacteria synthesize special adhesion proteins to build a matrix. When they

are fixed, they emit signaling molecules that "recruit" new bacteria, in addition, the division

of bacteria already fixed in the biofilm is stimulated.

CONCLUSION

Vaginal metronidazole preparations promote the eradication of pathogenic planktonic

microorganisms, do not have a systemic effect, and the applicator ensures its rapid entry into

the infection site. The use of metronidazole is accompanied by a minimal number of adverse

reactions.

LITERATURE

1. Ли С.К., Ким Ч.Дж., Ким Д.Дж., Канг Дж.Х. Иммунные клетки в женских

репродуктивных путях. Immune Netw. 2015;15:16-26. doi:10.4110/in.2015.15.1.16.

2. Бондаренко К.Р., Озолиня Л.А., Бондаренко В.М. Патогенетические аспекты

вагинального дисбиоза и современные возможности его коррекции. Акушерство и

гинекология. 2014;8:127-132.

3. Кампишиано Г., Занотта Н., Ликастро Д., Де Сета Ф., Комар М. Микробиом in vivo

и связанные с ним иммунные маркеры: новые данные о патогенезе вагинального

дисбиоза. Sci Rep. 2018;8:2307. doi:10.1038/s41598-018-20649-x.

4. Чен А., МакКинли С.А., Ван С., Ши Ф., Муха П.Дж., Форест М.Г., Лай С.К.

Временные взаимодействия антител с муцином создают динамический молекулярный

щит против вирусной инвазии. Биофизический журнал. 2014;106:2028–2036. doi:

10.1016/j.bpj.2014.02.038.


background image

w

w

w

.a

ca

de

m

icp

ub

lis

he

rs

.o

rg

Vo

lu

m

e

5,

Fe

br

ua

ry

,2

02

5

,

M

ED

IC

AL

SC

IE

N

CE

S.

IM

PA

CT

FA

CT

OR

:7

,8

9

5. Ли И., Джин Л., Чен Т. Влияние секреторного IgA на иммунную систему слизистых

оболочек. Biomed Res Int. 2020;2020:2032057. doi:10.1155/2020/2032057.

6. Анатар М.Н., Бирн Э.Х., Доэрти К.Е., Боуман Б.А., Ямамото Х.С., Сумиллон М. и

др. Цервикально-вагинальные бактерии являются основным фактором, влияющим на

воспалительные реакции организма в женских половых путях. Иммунитет.

2015;42(5):965–976. doi:10.1016/j.immuni.2015.04.019.

7. Риццо А., Лосаччо А., Каррателли К.Р. Lactobacillus crispatus модулирует защиту

эпителиальных клеток от Candida albicans посредством Toll-подобных рецепторов 2 и

4, интерлейкина 8 и бета-дефенсинов 2 и 3 человека. Immunol Lett. 2013;156(1-2):102-

109. doi:10.1016/j.imlet.2013.08.013.

8. Бурменская О.В., Байрамова Г.Р., Непша О.С. и др. Видовой состав лактобактерий

при неспецифическом вагините и бактериальном вагинозе и его влияние на местный

иммунитет. Акушерство и гинекология. 2014;1:41-45.

9. Kyongo JK, Jespers V, Goovaerts O, Michiels J, Menten J, Fichorova RN и др. Поиск

растворимых и клеточных биомаркеров нижних отделов женских половых путей:

определение уровней и предикторов в когорте здоровых женщин европеоидной расы.

PLoS One. 2012;7(8):e43951. doi:10.1371/journal.pone.0043951.

10. Будиловская О.В., Шипицына Е.В., Спасибова Е.В. и др. Дифференциальная

экспрессия генов местного иммунного ответа во влагалище: значение для диагностики

вагинальных инфекций. Bull ExpBiol Med. 2020;168:646-650. doi:10.1007/s10517-020-

04771-3.

11. Российское общество дерматовенерологов и косметологов. Федеральные

клинические рекомендации. Дерматовенерология 2015. Болезни кожи. Инфекции,

передаваемые половым путем. М.; 2016: 645–54. [Rossiiskoe obshchestvo

dermatovenerologov

i

kosmetologov.

Federal'nye

klinicheskie

rekomendatsii.

Dermatovenerologiya 2015. Bolezni kozhi. Infektsii, peredavaemye polovym putem. M.;

2016: 645–54. (in Russian)]

12. Решетько О.В., Луцевич К.А. Бактериальный вагиноз при беременности:

современное состояние проблемы и значение фармакотерапии. Клин. микробиол.

антимикроб. химиотер. 2007; 9(4): 337–50. [Reshet'ko O.V., Lutsevich K.A. Bakterial'nyi

vaginoz pri beremennosti: sovremennoe sostoyanie problemy i znachenie farmakoterapii.

Klin. mikrobiol. antimikrob. khimioter. 2007; 9(4): 337–50. (in Russian)]

13. Хамидова М. Г. ИЗУЧЕНИЕ РАСТЕНИЙ, ПРИМЕНЯЕМЫХ ПРИ

ЗАБОЛЕВАНИЯХ ПОЧЕК, И ПРЕПАРАТОВ ИЗ ИХ //SCIENTIFIC JOURNAL OF

APPLIED AND MEDICAL SCIENCES. – 2024. – Т. 3. – №. 5. – С. 381-386.

14.

Хамидова,

Муштарибегим

Гайратовна.

"ИЗУЧЕНИЕ

РАСТЕНИЙ,

ПРИМЕНЯЕМЫХ ПРИ ЗАБОЛЕВАНИЯХ ПОЧЕК, И ПРЕПАРАТОВ ИЗ

ИХ."

SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES

3.5 (2024): 381-

386.


background image

w

w

w

.a

ca

de

m

icp

ub

lis

he

rs

.o

rg

Vo

lu

m

e

5,

Fe

br

ua

ry

,2

02

5

,

M

ED

IC

AL

SC

IE

N

CE

S.

IM

PA

CT

FA

CT

OR

:7

,8

9

15. Хамидова, М. Г. (2024). ИЗУЧЕНИЕ РАСТЕНИЙ, ПРИМЕНЯЕМЫХ ПРИ

ЗАБОЛЕВАНИЯХ ПОЧЕК, И ПРЕПАРАТОВ ИЗ ИХ.

SCIENTIFIC JOURNAL OF

APPLIED AND MEDICAL SCIENCES

,

3

(5), 381-386.

16. Gayratovna H. M. STUDY OF PLANTS USED FOR KIDNEY DISEASES AND

PREPARATIONS FROM THEM //SCIENTIFIC JOURNAL OF APPLIED AND

MEDICAL SCIENCES. – 2024. – Т. 3. – №. 5. – С. 352-357.

17. Gayratovna, Hamidova Mushtaribegim. "STUDY OF PLANTS USED FOR KIDNEY

DISEASES AND PREPARATIONS FROM THEM."

SCIENTIFIC JOURNAL OF

APPLIED AND MEDICAL SCIENCES

3.5 (2024): 352-357.

18. Gayratovna, H. M. (2024). STUDY OF PLANTS USED FOR KIDNEY DISEASES

AND PREPARATIONS FROM THEM.

SCIENTIFIC JOURNAL OF APPLIED AND

MEDICAL SCIENCES

,

3

(5), 352-357.

19.

Amsel R., Totten P.A., Spiegel C.A., Chen K.C., Eschenbach D., Holmes K.K.

Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am.

J. Med. 1983; 74(1): 14–22.

20. Klebanoff S.J., Hillier S.L., Eschenbach D.A., Waltersdorph A.M. Control of the

microbial flora of the vagina by H2O2-generating lactobacilli. J. Infect. Dis. 1991; 164(1):

94–100.

21. Ramirez N., Abel-Santos E. Requirements for germination of Clostridium sordellii

spores in vitro. J. Bacteriol. 2010; 192(2): 418–25. DOI: 10.1128/JB.01226-09

22. Peeters M., Piot P. Adhesion of Gardnerella vaginalis to vaginal epithelial cells:

variables affecting adhesion and inhibition by metronidazole. Genitourin. Med. 1985; 61(6):

391–5.

23. Stamey T.A., Kaufman M.F. Studies of introital colonization in women with recurrent

urinary infections. II. A comparison of growth in normal vaginal fluid of common versus

uncommon serogroups of Escherichia coli. J. Urol. 1975; 114(2): 264–7.

24. Hanna N.F., Taylor-Robinson D., Kalodiki-Karamanoli M., Harris J.R., McFadyen I.R.

The relation between vaginal pH and the microbiological status in vaginitis. Br. J. Obstet.

Gynaecol. 1985; 92(12): 1267–71.

25. Liu H., Liu X., Zhang J., Chen J. Acetate accumulation and shift of bacterial community

during anaerobic sewage sludge fermentation by pH adjustment. Wei Sheng Wu Xue Bao.

2009; 49(12): 1643–9.

26. Fredricks D.N., Fiedler T.L., Marrazzo J.M. Molecular identification of bacteria

associated with bacterial vaginosis. N. Engl. J. Med. 2005; 353(18): 1899–911. DOI:

10.1056/NEJMoa043802


background image

w

w

w

.a

ca

de

m

icp

ub

lis

he

rs

.o

rg

Vo

lu

m

e

5,

Fe

br

ua

ry

,2

02

5

,

M

ED

IC

AL

SC

IE

N

CE

S.

IM

PA

CT

FA

CT

OR

:7

,8

9

27. Swidsinski A., Mendling W., Loening-Baucke V., Swidsinski S., Dörffel Y., Scholze J.

et al. An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after

standard therapy with oral metronidazole. Am. J. Obstet. Gynecol. 2008; 198(1): 97.e1–6.

DOI: 10.1016/j.ajog.2007.06.039

28. An D., Parsek M.R. The promise and peril of transcriptional profiling in biofilm

communities. Curr. Opin. Microbiol. 2007; 10(3): 292–6. DOI: 10.1016/j.mib.2007.05.011

29. Patterson J.L., Girerd P.H., Karjane N.W., Jefferson K.K. Effect of biofilm phenotype on

resistance of Gardnerella vaginalis to hydrogen peroxide and lactic acid. Am. J. Obstet.

Gynecol. 2007; 197(2): 170. e1–7. DOI: 10.1016/j.ajog.2007.02.027

30. Verstaelen H. Cutting edge: the vaginal microflora and bacterial vaginosis. Verh. K.

Acad. Geneeskd. Belg. 2008; 70(3): 147–74.

References

Ли С.К., Ким Ч.Дж., Ким Д.Дж., Канг Дж.Х. Иммунные клетки в женских репродуктивных путях. Immune Netw. 2015;15:16-26. doi:10.4110/in.2015.15.1.16.

Бондаренко К.Р., Озолиня Л.А., Бондаренко В.М. Патогенетические аспекты вагинального дисбиоза и современные возможности его коррекции. Акушерство и гинекология. 2014;8:127-132.

Кампишиано Г., Занотта Н., Ликастро Д., Де Сета Ф., Комар М. Микробиом in vivo и связанные с ним иммунные маркеры: новые данные о патогенезе вагинального дисбиоза. Sci Rep. 2018;8:2307. doi:10.1038/s41598-018-20649-x.

Чен А., МакКинли С.А., Ван С., Ши Ф., Муха П.Дж., Форест М.Г., Лай С.К. Временные взаимодействия антител с муцином создают динамический молекулярный щит против вирусной инвазии. Биофизический журнал. 2014;106:2028–2036. doi: 10.1016/j.bpj.2014.02.038.

Ли И., Джин Л., Чен Т. Влияние секреторного IgA на иммунную систему слизистых оболочек. Biomed Res Int. 2020;2020:2032057. doi:10.1155/2020/2032057.

Анатар М.Н., Бирн Э.Х., Доэрти К.Е., Боуман Б.А., Ямамото Х.С., Сумиллон М. и др. Цервикально-вагинальные бактерии являются основным фактором, влияющим на воспалительные реакции организма в женских половых путях. Иммунитет. 2015;42(5):965–976. doi:10.1016/j.immuni.2015.04.019.

Риццо А., Лосаччо А., Каррателли К.Р. Lactobacillus crispatus модулирует защиту эпителиальных клеток от Candida albicans посредством Toll-подобных рецепторов 2 и 4, интерлейкина 8 и бета-дефенсинов 2 и 3 человека. Immunol Lett. 2013;156(1-2):102-109. doi:10.1016/j.imlet.2013.08.013.

Бурменская О.В., Байрамова Г.Р., Непша О.С. и др. Видовой состав лактобактерий при неспецифическом вагините и бактериальном вагинозе и его влияние на местный иммунитет. Акушерство и гинекология. 2014;1:41-45.

Kyongo JK, Jespers V, Goovaerts O, Michiels J, Menten J, Fichorova RN и др. Поиск растворимых и клеточных биомаркеров нижних отделов женских половых путей: определение уровней и предикторов в когорте здоровых женщин европеоидной расы. PLoS One. 2012;7(8):e43951. doi:10.1371/journal.pone.0043951.

Будиловская О.В., Шипицына Е.В., Спасибова Е.В. и др. Дифференциальная экспрессия генов местного иммунного ответа во влагалище: значение для диагностики вагинальных инфекций. Bull ExpBiol Med. 2020;168:646-650. doi:10.1007/s10517-020-04771-3.

Российское общество дерматовенерологов и косметологов. Федеральные клинические рекомендации. Дерматовенерология 2015. Болезни кожи. Инфекции, передаваемые половым путем. М.; 2016: 645–54. [Rossiiskoe obshchestvo dermatovenerologov i kosmetologov. Federal'nye klinicheskie rekomendatsii. Dermatovenerologiya 2015. Bolezni kozhi. Infektsii, peredavaemye polovym putem. M.; 2016: 645–54. (in Russian)]

Решетько О.В., Луцевич К.А. Бактериальный вагиноз при беременности: современное состояние проблемы и значение фармакотерапии. Клин. микробиол. антимикроб. химиотер. 2007; 9(4): 337–50. [Reshet'ko O.V., Lutsevich K.A. Bakterial'nyi vaginoz pri beremennosti: sovremennoe sostoyanie problemy i znachenie farmakoterapii. Klin. mikrobiol. antimikrob. khimioter. 2007; 9(4): 337–50. (in Russian)]

Хамидова М. Г. ИЗУЧЕНИЕ РАСТЕНИЙ, ПРИМЕНЯЕМЫХ ПРИ ЗАБОЛЕВАНИЯХ ПОЧЕК, И ПРЕПАРАТОВ ИЗ ИХ //SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES. – 2024. – Т. 3. – №. 5. – С. 381-386.

Хамидова, Муштарибегим Гайратовна. "ИЗУЧЕНИЕ РАСТЕНИЙ, ПРИМЕНЯЕМЫХ ПРИ ЗАБОЛЕВАНИЯХ ПОЧЕК, И ПРЕПАРАТОВ ИЗ ИХ." SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES 3.5 (2024): 381-386.

Хамидова, М. Г. (2024). ИЗУЧЕНИЕ РАСТЕНИЙ, ПРИМЕНЯЕМЫХ ПРИ ЗАБОЛЕВАНИЯХ ПОЧЕК, И ПРЕПАРАТОВ ИЗ ИХ. SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES, 3(5), 381-386.

Gayratovna H. M. STUDY OF PLANTS USED FOR KIDNEY DISEASES AND PREPARATIONS FROM THEM //SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES. – 2024. – Т. 3. – №. 5. – С. 352-357.

Gayratovna, Hamidova Mushtaribegim. "STUDY OF PLANTS USED FOR KIDNEY DISEASES AND PREPARATIONS FROM THEM." SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES 3.5 (2024): 352-357.

Gayratovna, H. M. (2024). STUDY OF PLANTS USED FOR KIDNEY DISEASES AND PREPARATIONS FROM THEM. SCIENTIFIC JOURNAL OF APPLIED AND MEDICAL SCIENCES, 3(5), 352-357.

Amsel R., Totten P.A., Spiegel C.A., Chen K.C., Eschenbach D., Holmes K.K. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am. J. Med. 1983; 74(1): 14–22.

Klebanoff S.J., Hillier S.L., Eschenbach D.A., Waltersdorph A.M. Control of the microbial flora of the vagina by H2O2-generating lactobacilli. J. Infect. Dis. 1991; 164(1): 94–100.

Ramirez N., Abel-Santos E. Requirements for germination of Clostridium sordellii spores in vitro. J. Bacteriol. 2010; 192(2): 418–25. DOI: 10.1128/JB.01226-09

Peeters M., Piot P. Adhesion of Gardnerella vaginalis to vaginal epithelial cells: variables affecting adhesion and inhibition by metronidazole. Genitourin. Med. 1985; 61(6): 391–5.

Stamey T.A., Kaufman M.F. Studies of introital colonization in women with recurrent urinary infections. II. A comparison of growth in normal vaginal fluid of common versus uncommon serogroups of Escherichia coli. J. Urol. 1975; 114(2): 264–7.

Hanna N.F., Taylor-Robinson D., Kalodiki-Karamanoli M., Harris J.R., McFadyen I.R. The relation between vaginal pH and the microbiological status in vaginitis. Br. J. Obstet. Gynaecol. 1985; 92(12): 1267–71.

Liu H., Liu X., Zhang J., Chen J. Acetate accumulation and shift of bacterial community during anaerobic sewage sludge fermentation by pH adjustment. Wei Sheng Wu Xue Bao. 2009; 49(12): 1643–9.

Fredricks D.N., Fiedler T.L., Marrazzo J.M. Molecular identification of bacteria associated with bacterial vaginosis. N. Engl. J. Med. 2005; 353(18): 1899–911. DOI: 10.1056/NEJMoa043802

Swidsinski A., Mendling W., Loening-Baucke V., Swidsinski S., Dörffel Y., Scholze J. et al. An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. Am. J. Obstet. Gynecol. 2008; 198(1): 97.e1–6. DOI: 10.1016/j.ajog.2007.06.039

An D., Parsek M.R. The promise and peril of transcriptional profiling in biofilm communities. Curr. Opin. Microbiol. 2007; 10(3): 292–6. DOI: 10.1016/j.mib.2007.05.011

Patterson J.L., Girerd P.H., Karjane N.W., Jefferson K.K. Effect of biofilm phenotype on resistance of Gardnerella vaginalis to hydrogen peroxide and lactic acid. Am. J. Obstet. Gynecol. 2007; 197(2): 170. e1–7. DOI: 10.1016/j.ajog.2007.02.027

Verstaelen H. Cutting edge: the vaginal microflora and bacterial vaginosis. Verh. K. Acad. Geneeskd. Belg. 2008; 70(3): 147–74.